Baxter International Inc is a medical instruments & supplies business based in the US. Baxter International shares (BAX) are listed on the NYSE and all prices are listed in US Dollars. Baxter International employs 50,000 staff and has a trailing 12-month revenue of around USD$12.2 billion.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Since the stock market crash in March caused by coronavirus, Baxter International's stock price has had significant negative movement.
Its last market close was $79.7, which is 14.00% down on its pre-crash value of $92.67 and 15.34% up on the lowest point reached during the March crash when the stocks fell as low as $69.1.
If you had bought $1,000 worth of Baxter International stocks at the start of February 2020, those stocks would have been worth $800.68 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $888.66.
|Latest market close||$79.70|
|52-week range||$72.86 - $87.70|
|50-day moving average||$80.57|
|200-day moving average||$81.36|
|Wall St. target price||$94.20|
|Dividend yield||$1.015 (1.27%)|
|Earnings per share (TTM)||$2.18|
Note: The dollar amounts in the table below are in Canadian dollars.
|1 week (2021-10-08)||-0.62%|
|1 month (2021-09-17)||-4.68%|
|3 months (2021-07-16)||-2.11%|
|6 months (2021-04-16)||-7.93%|
|1 year (2020-10-16)||-2.59%|
|2 years (2019-10-18)||-9.42%|
|3 years (2018-10-18)||13.10%|
|5 years (2016-10-18)||65.83%|
Valuing Baxter International stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Baxter International's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Baxter International's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 37x. In other words, Baxter International shares trade at around 37x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Baxter International's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.4857. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Baxter International's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Baxter International's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.8 billion.
The EBITDA is a measure of a Baxter International's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$12.2 billion|
|Operating margin TTM||15.71%|
|Gross profit TTM||$4.7 billion|
|Return on assets TTM||6.12%|
|Return on equity TTM||13.55%|
|Market capitalisation||$39.8 billion|
TTM: trailing 12 months
There are currently 7.5 million Baxter International shares held short by investors – that's known as Baxter International's "short interest". This figure is 18.8% up from 6.3 million last month.
There are a few different ways that this level of interest in shorting Baxter International shares can be evaluated.
Baxter International's "short interest ratio" (SIR) is the quantity of Baxter International shares currently shorted divided by the average quantity of Baxter International shares traded daily (recently around 3.8 million). Baxter International's SIR currently stands at 1.95. In other words for every 100,000 Baxter International shares traded daily on the market, roughly 1950 shares are currently held short.
However Baxter International's short interest can also be evaluated against the total number of Baxter International shares, or, against the total number of tradable Baxter International shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Baxter International's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Baxter International shares in existence, roughly 20 shares are currently held short) or 0.015% of the tradable shares (for every 100,000 tradable Baxter International shares, roughly 15 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Baxter International.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Baxter International.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 24.49
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Baxter International's overall score of 24.49 (as at 01/01/2019) is nothing to write home about – landing it in it in the 47th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Baxter International is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 1.01/100
Baxter International's environmental score of 1.01 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Baxter International is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 16.22/100
Baxter International's social score of 16.22 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Baxter International is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 6.28/100
Baxter International's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Baxter International is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Baxter International scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Baxter International hasn't always managed to keep its nose clean.
Dividend payout ratio: 32.92% of net profits
Recently Baxter International has paid out, on average, around 32.92% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.41% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Baxter International shareholders could enjoy a 1.41% return on their shares, in the form of dividend payments. In Baxter International's case, that would currently equate to about $1.015 per share.
While Baxter International's payout ratio might seem fairly standard, it's worth remembering that Baxter International may be investing much of the rest of its net profits in future growth.
Baxter International's most recent dividend payout was on 1 October 2021. The latest dividend was paid out to all shareholders who bought their shares by 2 September 2021 (the "ex-dividend date").
Baxter International's shares were split on a 1841:1000 basis on 1 July 2015. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1841 shares. This wouldn't directly have changed the overall worth of your Baxter International shares – just the quantity. However, indirectly, the new 45.7% lower share price could have impacted the market appetite for Baxter International shares which in turn could have impacted Baxter International's share price.
Over the last 12 months, Baxter International's shares have ranged in value from as little as $72.8561 up to $87.6993. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Baxter International's is 0.6138. This would suggest that Baxter International's shares are less volatile than average (for this exchange).
Baxter International Inc. , through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules.
Stock trading doesn’t have to be expensive. Using Finder’s proprietary algorithm, we’ve identified the best cheap Canadian and US stocks to buy now.Read more…
Cue Health—developer of a COVID-19 self-testing kit with conditional approval in the US, Canada, European Union and India—has gone public. Here’s how to buy in.Read more…
Steps to owning and managing ARBK stock, with 24-hour and historical pricing before you buy.Read more…
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.